Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5398362 | 0.92 | ALDH1A1 (0.41) | SLC16A1ALDH1A1MEN1USP2LMNA | |
| SCHEMBL5393463 | 0.91 | HPGD (0.44) | SLC16A1ALDH1A1MEN1USP2LMNA | |
| SCHEMBL5402662 | 0.90 | MEN1 (0.40) | SLC16A1ALDH1A1MEN1USP2LMNA | |
| SCHEMBL5395371 | 0.88 | SLC16A1 (0.52) | SLC16A1ALDH1A1MEN1USP2LMNA | |
| SCHEMBL5403905 | 0.88 | TSHR (0.43) | ALDH1A1MEN1USP2LMNAMAPT | |
| SCHEMBL5398837 | 0.87 | NPBWR1 (0.40) | GPR18ALDH1A1MEN1USP2LMNA | |
| SCHEMBL5400124 | 0.86 | NPBWR1 (0.41) | ALDH1A1MEN1USP2LMNAMAPT | |
| SCHEMBL5415361 | 0.85 | MAPT (0.44) | ALDH1A1MEN1USP2LMNAMAPT | |
| SCHEMBL5403289 | 0.85 | NPBWR1 (0.49) | SLC16A1ALDH1A1LMNAMAPTTSHR | |
| SCHEMBL5418055 | 0.85 | THRB (0.42) | SLC16A1ALDH1A1MEN1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | PIK3CD 284/4885SLC16A1 4140/4885CNR1 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.